Canopy Growth (CGC, $36.12) got a rating downgrade from Jefferies
Cannabis company Canopy Growth got a rating downgrade from Jefferies on valuation.
Analysts at Jefferies lowered their rating on the company’s shares to underperform from hold. Their price target is $23.03.
Analyst Owen Bennett argued that while bulls will suggest that Canopy's multiple is deserved given possible near-term U.S. entry, it is still “too expensive” even though its U.S. optionality is the best among Canadian names.
The firm indicated that Canopy’s option to acquire U.S. multistate operator Acreage Holdings will likely be bolstered in the event of a change in U.S. federal cannabis laws. But for now both Canopy and Acreage are unprofitable, noted Bennett. According to the analyst, the fundamental outlook for other U.S. companies is "far superior".
CGC in +5.70% Uptrend, growing for three consecutive days on November 26, 2025
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CGC advanced for three days, in of 201 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CGC's RSI Oscillator exited the oversold zone, of 53 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 26, 2025. You may want to consider a long position or call options on CGC as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CGC just turned positive on November 24, 2025. Looking at past instances where CGC's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
CGC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for CGC moved below the 200-day moving average on November 10, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CGC entered a downward trend on November 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.790) is normal, around the industry mean (16.589). P/E Ratio (0.000) is within average values for comparable stocks, (73.316). CGC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.951). CGC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (1.109) is also within normal values, averaging (55.567).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of medical marijuana
Industry PharmaceuticalsGeneric
Advertisement